Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone
Sponsor: Children's Oncology Group
Listed as NCT00033293, this PHASE3 trial focuses on Localized Resectable Neuroblastoma and Localized Unresectable Neuroblastoma and remains completed. Sponsored by Children's Oncology Group, it has been updated 13 times since 2004, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2023 — May 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Feb 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2021 — Feb 2022 [monthly]
Unknown Status PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Apr 2020 — Nov 2020 [monthly]
Unknown Status PHASE3
Status: Completed → Unknown Status
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .